# A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)

> **NCT06241950** · PHASE1 · TERMINATED · sponsor: **Sarepta Therapeutics, Inc.** · enrollment: 5 (actual)

## Conditions studied

- Duchenne Muscular Dystrophy

## Interventions

- **GENETIC:** delandistrogene moxeparvovec
- **BIOLOGICAL:** imlifidase

## Key facts

- **NCT ID:** NCT06241950
- **Lead sponsor:** Sarepta Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-01-29
- **Primary completion:** 2025-10-10
- **Final completion:** 2025-10-10
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Study is being terminated due to a business decision.
- **Last updated:** 2025-11-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06241950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06241950, "A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06241950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*